Earn points on every order New products in stock Free 51-page beginner’s guide
← Back to Compound Library

DULAGLUTIDE

An FDA-approved once-weekly GLP-1 (brand Trulicity), used for type-2 diabetes and weight management. Same appetite-curbing, blood-sugar-lowering family as semaglutide, with simple weekly dosing.

Research referenceCommunity compiled

Molecular profile

What this material is, and why it has no fixed molecular structure.

Class
GLP-1 analog fused to an Fc fragment
Receptor / pathway
GLP-1 receptor
Class from the published fusion structure; no small-molecule formula applies.
Research & reference information

This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.

Overview

Dulaglutide (Trulicity) is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist engineered as a fusion protein linked to an IgG4-Fc fragment.

What problem it targets: It targets poorly controlled Type 2 diabetes, chronic hyperglycemia, high cardiovascular event risk, and obesity-driven metabolic dysfunction.

What It Does

• Enhances glucose-dependent insulin secretion: Activates pancreatic beta-cell GLP-1 receptors only when blood sugar is elevated, virtually eliminating the risk of sudden hypoglycemia.

• Shuts down inappropriate post-meal glucagon: Inhibits hepatic glucose overproduction, stopping the liver from releasing unnecessary sugar into the blood.

• Slows digestion and suppresses appetite: Delays gastric emptying and acts on brain satiety centers to curb food cravings and lower total daily caloric intake.

• Realistic expectations: Administered as a convenient once-weekly injection. Produces dependable, steady reductions in HbA1c and moderate weight reduction, with mild initial nausea being the primary side effect.

Reconstitution

Vial sizeBAC water / SolventConcentration
5 mg+ 1 mL5 mg/mL
10 mg+ 2 mL5 mg/mL

Protocol

PhaseFrequencyDoseUnits (5 mg/mL)Notes
Weeks 1–4Once weekly0.75 mg15uStarting dose (FDA Trulicity).
Weeks 5–8Once weekly1.5 mg30uStep up if tolerated.
Weeks 9–12Once weekly3.0 mg60u
Week 13+Once weekly4.5 mg90uMax labeled dose. Cycle: escalate every 4 weeks as tolerated to the 4.5 mg max. Continuous use is standard for the indication. Timing: same day each week, any time, with or without food. FDA: approved as Trulicity for type-2 diabetes; weight loss is moderate vs semaglutide/tirzepatide. Women: Women lose more than men at the same dose but report more GI (start lower). In PCOS they improve cycles, lower free testosterone and raise ovulation; a real unplanned-pregnancy risk. Stop before conceiving. Men: In men, excess fat lowers testosterone; GLP-1 raises total testosterone, SHBG and gonadotropins as weight drops, and improves sperm and erectile function; and preserves fertility, unlike TRT (which suppresses sperm).

Handling & Stacking

Injection site
SubQ, abdomen/thigh/upper arm. Rotate.
Storage
  • Freeze-dried: -4°F.
  • Reconstituted: 36–46°F.
  • Best used within 28 days.
  • No clear reconstituted-potency data (the pen label gives an in-use date, not potency), so defer to the 28-day sterility limit. (Commercial Trulicity is pre-filled, refrigerated.)
Side effects
Nausea, diarrhea, vomiting, reduced appetite, injection-site reactions. GI effects dose-dependent.
What to expect
Lower blood sugar and appetite within weeks; moderate weight loss over months. Supply math 5mg → 10 vials | 10mg → 5 vials (12-wk titration to 4.5 mg/wk)
Pairs well with
Lipo-C / L-Carnitine (metabolic support). Do not combine with other GLP-1 / incretin agents
Avoid
Personal/family history of medullary thyroid carcinoma or MEN2. Prior pancreatitis. Pregnancy. Other GLP-1s

Safety & Patient Education

Contraindications
Personal/family history of medullary thyroid carcinoma or MEN2 (boxed warning) Prior pancreatitis Pregnancy and lactation Type 1 diabetes / diabetic ketoacidosis
Warnings
Thyroid C-cell tumors in rodents (boxed warning) Gallbladder disease with rapid weight loss Hypoglycemia when combined with insulin/sulfonylureas Diabetic retinopathy complications with rapid glucose improvement Acute kidney injury from dehydration (vomiting/diarrhea)
Drug interactions
Insulin / sulfonylureas: reduce dose to avoid hypoglycemia Delayed gastric emptying alters oral drug absorption Other GLP-1 agents: do not combine
Labs
  • Fasting glucose / HbA1c (baseline + periodic) Renal function with significant GI losses Lipase if pancreatitis suspected Resting heart rate (GLP-1s nudge it up a few bpm) Out of range?
  • Rising glucose/HbA1c = blood sugar creeping toward diabetes (recheck, tighten diet); a falling eGFR = kidney strain, usually dehydration (hydrate, hold the dose).
Stop criteria
Severe persistent abdominal pain (pancreatitis) Persistent vomiting / dehydration Signs of gallbladder disease (RUQ pain, jaundice) Pregnancy
Patient education
FDA-approved GLP-1, same class precautions as semaglutide Titrate every 4 weeks; most nausea is early and improves Hydrate and maintain protein intake Stop and seek care for severe abdominal pain or persistent vomiting
References
rxlist · dailymed · researchdosing · peptidedosages · GLP-1 sex differences · Jensterle 2020